Posted by Michael Wonder on 27 Jul 2020
TGA approves Zeposia for patients with multiple sclerosis
27 July 2020 - Zeposia has been approved under the Black Triangle Scheme.
The TGA has approved ozanimod hydrochloride (Zeposia) for the treatment of adult patients with relapsing forms of multiple sclerosis.
Ozanimod hydrochloride is a sphingosine 1-phosphate (S1P) receptor modulator, which binds with a high affinity to sphingosine 1-phosphate receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride is 10 fold more selective for S1P1 relative to S1P5 and has little activity on other S1P receptors (S1P2, S1P3, and S1P4).
